Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

Rombouts, Maurien D; Swart, Eleonora L.; Eertwegh, Alfons J.M. van den; Crul, Mirjam

doi:10.21873/anticanres.14062

Cited by 51 publications

(62 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with earlier studies, 18,36,37 the pooled rates demonstrated that infusion-related AEs, and infections were common, which might spring from the release of cytokines and/or other chemical mediators, 36 and the decreased immunoglobulin levels, 37 respectively. However, the rates of patients with infusion-related AEs and any infections were numerically higher, 11,37 and the infections mainly occurred in pulmonary and urinary, but did not present as herpetic rashes or tuberculosis reactivation when compared with the previous studies.…”

Section: Discussionsupporting

confidence: 89%

Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

Wang

Zhou

et al. 2021

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Background: The adverse events (AEs) of rituximab (RTX) for neuromyelitis optica spectrum disorder (NMOSD) are incompletely understood. Aim: To collate information on the reported the AEs of RTX in NMOSD and assess the quality of evidence. Methods: PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang Data, CBM, CNKI, VIP, clinicaltrials.gov, and so on were searched for studies with control groups as well as for case series that had assessed the RTX-associated AEs. The incidence of AEs and the comparison of AE risks among different therapies were pooled. The GRADE was developed for evidence quality. Results: A total of 3566 records were identified. Finally, 36 studies (4 RCTs, 6 crochet studies, 2 NRCTs, and 24 case series), including 1542 patients (1299 females and 139 males), were included for final analyses. Rates of patients with any AEs, any serious AEs (SAEs), infusion-related AEs, any infection, respiratory infection, urinary infection, and death were 28.57%, 5.66%, 27.01%, 17.36%, 4.76%, 4.76%, and 0.17%, respectively. The results from subgroup analysis showed that AE rates were most likely not associated with covariates such as duration of illness and study designs. Very low-quality evidence suggested that the risk ratios (RR) of any AEs (0.84, 95% CI = 00.42–1.69, p = 0.62) and any infections (1.24 95% CI = 0.18–8.61) of RTX were similar to that of azathioprine, and the RR of any AEs of RXT was akin to that of mycophenolate mofetil (0.66, 95% CI = 0.32–1.35 p = 0.26). Evidence of low to high quality showed the lower RR of RTX in other AEs, but not in infusion-related AEs. Strategies to handle AEs focused on symptomatic treatments. Conclusions: RTX is mostly safer than other immunosuppressants in NMOSD: the incidence of RTX-associated AEs was not high, and when present, the AEs were usually mild or moderate and could be well controlled. Given its efficacy and safety, RTX could be recommended as a first-line treatment for NMOSD.

show abstract

Section: Discussionsupporting

confidence: 89%

Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

Wang

Zhou

et al. 2021

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Although DEX was not used as premedication, the incidence of IRRs in the REGARD trial was lower than in the RAINBOW and RAISE trials. DEX and H 1 AT are generally used as anti-allergy premedication (1,5). However, the benefits of these drug combination are unknown, and suitable doses are not well established.…”

Section: Discussionmentioning

confidence: 99%

“…anticancer agents, mAbs may cause infusion-related reactions (IRRs) (1)(2)(3). Most IRRs are mild with symptoms such as chills, fever, nausea, skin rash, and pruritus.…”

mentioning

confidence: 99%

“…When released into the circulation, cytokines can produce a wide range of symptoms, characteristic of IRRs. Premedication with H1antihistamines (H 1 AT), acetaminophen, or corticosteroids is a common practice to prevent IRRs associated to mAb use (1,5). It is difficult to evaluate adverse events, such as IRRs, through prospective studies due to the unexpected nature of these events.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers

Goto

Yamaguchi

Hattori

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: To prevent infusion-related reactions (IRRs), H1-antihistamines (H 1 AT) are recommended as a premedication for monoclonal antibodies, such as Ramucirumab (RAM), even though there are H 1 AT-related side effects, such as drowsiness and dizziness. Here, we investigated the safety of H 1 AT-free RAM regimens in patients with solid cancer. Patients and Methods: We retrospectively reviewed the patients with solid cancer receiving RAM without H 1 AT at Osaka Medical College Hospital between 2015 and 2019. Results: Among the 123 registered patients, 58 were identified as eligible. The total number of RAM infusions was 291, and the median number of RAM administration was 4 cycles (range=1-23 cycles). IRRs were not observed in any patient. Conclusion: Although our data are preliminary and limited, H 1 AT-free RAM regimens may be a treatment option for cancer patients having a significant risk of developing H 1 AT-related side effects. Further studies are needed to confirm the safety of H 1 AT-free RAM regimens.Monoclonal antibodies (mAbs) have been widely used for the treatment of various malignancies (1-3). As most mAbs show lower toxicity than conventional anticancer agents, they are generally better tolerated (2-4). However, like other infused 3489 This article is freely accessible online.

show abstract

“…However, it is easy to relapse after these treatments, and the patients' survival rates are not significantly improved. Immunotherapy is useful for treating tumors, the mAbs bevacizumab, rituximab, and trastuzumab were already widely used against tumors outside the brain (75)(76)(77)(78)(79). But the current immunotherapy for medical glioma is costly and inefficient.…”

Section: The Application Of Phage Nanomaterials To Glioma Therapymentioning

confidence: 99%

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

et al. 2021

View full text Add to dashboard Cite

Glioma is a life-threatening malignant tumor. Resistance to traditional treatments and tumor recurrence present major challenges in treating and managing this disease, consequently, new therapeutic strategies must be developed. Crossing the blood-brain barrier (BBB) is another challenge for most drug vectors and therapy medications. Filamentous bacteriophage can enter the brain across the BBB. Compared to traditional drug vectors, phage-based drugs offer thermodynamic stability, biocompatibility, homogeneity, high carrying capacity, self-assembly, scalability, and low toxicity. Tumor-targeting peptides from phage library and phages displaying targeting peptides are ideal drug delivery agents. This review summarized recent studies on phage-based glioma therapy and shed light on the developing therapeutics phage in the personalized treatment of glioma.

show abstract

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

Cited by 51 publications

References 46 publications

Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

Contact Info

Product

Resources

About